1B-O1-1505 PDF
Development of LC/MS/MS methods for high molecular compounds, therapeutic peptide and antisense oligonucleotide, in the early drug discovery stage
Quantitative bioanalytical methods for high molecular weight compounds, therapeutic peptide, PEGylated/alkylated peptide and antisense oligonucleotide, have been developed by LC/MS/MS in the early drug discovery stage. For large molecular weight compounds, a ligand binding assay (LBA) is commonly employed for quantitative bioanalysis in biological samples. However, LBA might not be suitable, especially in the early drug discovery stage, due to several problems such as time-consuming process for method developments, less versatility for various candidate compounds and cross reactivity with structurally related molecules or metabolites. From this point of view, quantitative bioanalytical methods with LC/MS/MS have been increasingly promising. In this presentation, we will present key approaches in method developments of quantitative bioanalytical LC/MS/MS methods with high sensitivity and accuracy.